Intercept Pharmaceuticals (NASDAQ:ICPT) Lowered to Market Perform at Oppenheimer
Intercept Pharmaceuticals (NASDAQ:ICPT) was downgraded by Oppenheimer from an “outperform” rating to a “market perform” rating in a report released on Monday, MarketBeat Ratings reports. They currently have a $46.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $124.00. Oppenheimer’s price target would indicate a potential downside of 3.99% from the stock’s previous close.
Several other equities analysts have also recently commented on ICPT. Needham & Company LLC reiterated a “buy” rating and set a $150.00 target price on shares of Intercept Pharmaceuticals in a research note on Monday, May 11th. ValuEngine upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, May 3rd. Raymond James cut shares of Intercept Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and cut their target price for the company from $145.00 to $115.00 in a research note on Friday, May 22nd. BidaskClub raised shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. Finally, Wells Fargo & Co lowered shares of Intercept Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $146.00 to $46.00 in a report on Monday. Eighteen investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Intercept Pharmaceuticals has a consensus rating of “Hold” and an average price target of $81.48.
Shares of Intercept Pharmaceuticals stock opened at $47.91 on Monday. The firm has a fifty day simple moving average of $78.84 and a 200-day simple moving average of $88.09. The company has a current ratio of 4.19, a quick ratio of 4.19 and a debt-to-equity ratio of 10.32. Intercept Pharmaceuticals has a 1-year low of $44.50 and a 1-year high of $125.00. The stock has a market capitalization of $2.55 billion, a price-to-earnings ratio of -4.47 and a beta of 1.82.
In other Intercept Pharmaceuticals news, Director Paolo Fundaro sold 595,578 shares of the stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $84.60, for a total transaction of $50,385,898.80. Following the sale, the director now owns 19,433 shares of the company’s stock, valued at approximately $1,644,031.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have sold 595,817 shares of company stock worth $50,405,516. Insiders own 23.70% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Efficient Wealth Management LLC acquired a new position in Intercept Pharmaceuticals during the 1st quarter valued at about $31,000. PNC Financial Services Group Inc. lifted its position in Intercept Pharmaceuticals by 42.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 790 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 234 shares during the period. First Mercantile Trust Co. lifted its position in Intercept Pharmaceuticals by 17.5% during the 1st quarter. First Mercantile Trust Co. now owns 938 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 140 shares during the period. Credit Agricole S A acquired a new position in Intercept Pharmaceuticals during the 1st quarter valued at about $76,000. Finally, Sunbelt Securities Inc. acquired a new position in Intercept Pharmaceuticals during the 4th quarter valued at about $41,823,000. Institutional investors own 76.46% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Read More: Example of operating income, EBIT and EBITDA
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.